

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web  
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates  
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update  
frequency  
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
NEWS 6 Mar 08 Gene Names now available in BIOSIS  
NEWS 7 Mar 22 TOXLIT no longer available  
NEWS 8 Mar 22 TRCTHERMO no longer available  
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS  
and USPATFULL  
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY  
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.  
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 14 Apr 09 ZDB will be removed from STN  
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 19 Jun 03 New e-mail delivery for search results now available  
NEWS 20 Jun 10 MEDLINE Reload  
NEWS 21 Jun 10 PCTFULL has been reloaded  
NEWS 22 Jul 02 FOREGE no longer contains STANDARDS file segment  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:52:31 ON 17 JUL 2002

=> file medline embase biosis scisearch caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:52:45 ON 17 JUL 2002

FILE 'EMBASE' ENTERED AT 15:52:45 ON 17 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:52:45 ON 17 JUL 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 15:52:45 ON 17 JUL 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 15:52:45 ON 17 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s IgE  
L1 108894 IGE

=> s l1 and canine  
L2 0 L1 AND CANNINE

=> s l1 and canine  
L3 494 L1 AND CANINE

=> s l3 and CH3  
L4 1 L3 AND CH3

=> d l4 cbib abs

L4 ANSWER 1 OF 1 SCISEARCH COPYRIGHT 2002 ISI (R)

2000:407589 The Genuine Article (R) Number: 317PX. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Ghetie V (Reprint); Ward E S. UNIV TEXAS, SW MED CTR, CTR IMMUNOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 (Reprint); UNIV TEXAS, SW MED CTR, CTR CANC IMMUNOBIOI, DALLAS, TX 75235. ANNUAL REVIEW OF IMMUNOLOGY (JUL 2000) Vol. 18, pp. 739-766. Publisher: ANNUAL REVIEWS. 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139. ISSN: 0732-0582. Pub. country: USA. Language: English.

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Multiple functions have recently been identified for the neonatal Fc receptor FcRn. In addition, a human homolog of the rodent forms of FcRn has been identified and characterized. This major histocompatibility complex class I-related receptor plays a role in the passive delivery of immunoglobulin (Ig)Gs from mother to young and the regulation of serum IgG levels. In addition, FcRn expression in tissues such as liver, mammary gland, and adult intestine suggests that it may modulate IgG transport at these sites. These diverse functions are apparently brought about by the ability of FcRn to bind IgGs and transport them within and across cells. However, the molecular details as to how FcRn traffics within cells have yet to be fully understood, although in vitro systems have been developed for this purpose. The molecular nature of the FcRn-IgG interaction has been studied extensively and encompasses residues located at the CH2-CH3 domain interface of the Fc region of IgG. These Fc amino acids are highly conserved in rodents and man and interact with residues primarily located on the alpha 2 domain of FcRn. Thus, it is now possible

to engineer IgGs with altered affinities for FcRn, and this has relevance to the modulation of **IgE** serum half-life and maternofetal IgG transport for therapeutic applications.

=> s l3 and CH4

L5                   0 L3 AND CH4

=> s l3 and fusion

L6                   19 L3 AND FUSION

=> dup remove l6

PROCESSING COMPLETED FOR L6

L7                   6 DUP REMOVE L6 (13 DUPLICATES REMOVED)

=> d l7 1-6 cbib abs

L7   ANSWER 1 OF 6

MEDLINE

DUPLICATE 1

2001558505   Document Number: 21491203.   PubMed ID: 11604166.   Recombinant

**canine** IL-13 receptor alpha2-Fc **fusion** protein inhibits **canine** allergen-specific-IgE production in vitro by peripheral blood mononuclear cells from allergic dogs. Tang L; Boroughs K L; Morales T; Stedman K; Sellins K; Clarke K; McDermott M; Yang S; McCall C. (Heska Corporation, 1613 Prospect Parkway, Fort Collins, CO 80525, USA.. tangl@heska.com) . VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, (2001 Nov) 83 (1-2) 115-22. Journal code: 8002006. ISSN: 0165-2427. Pub. country: Netherlands. Language: English.

AB   Human IL-13, like IL-4, is involved in the regulation of B-cell development, **IgE** synthesis and allergic responses. However, because IL-13 does not affect either murine Ig class switching or **IgE** production in vitro, the use of murine models to study the role of IL-13 in **IgE**-mediated diseases has been limited. In this communication, we report that recombinant protein of **canine** IL-13 (rcall-13) stimulates production of allergen-specific-IgE in vitro by peripheral blood mononuclear cells (PBMC) from flea allergen-sensitized dogs, and that this stimulation activity is specifically inhibited by recombinant protein of **canine** IL-13Ralpha2 and Fc fragment of **canine** IgG heavy chain (rcall-13Ralpha2-Fc). The data suggest that the regulatory effects of IL-13 on **IgE** production in **canine** PBMC are similar to those reported in humans. Thus, **canine** IL-13 may be a central mediator of allergic diseases in dogs, and allergic dogs may be excellent models for research on **IgE**-mediated diseases in humans.

L7   ANSWER 2 OF 6   BIOSIS   COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2

2001:175320   Document No.: PREV200100175320.   Soluble **canine** IL-13

receptor alpha2-Fc **fusion** protein inhibits **canine** allergen-specific-IgE production stimulated by IL-13 in vitro. Tang, Liang (1); Boroughs, Karen (1); Stedman, Kim E. (1); Sellins, Karen (1); Morales, Tony (1); McDermott, Martin (1); Yang, Shumin (1); McCall, Catherine A. (1). (1) Heska Corporation, Fort Collins, CO USA. Journal of Allergy and Clinical Immunology, (February, 2001) Vol. 107, No. 2, pp. S91. print. Meeting Info.: 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology New Orleans, Louisiana, USA March 16-21, 2001 ISSN: 0091-6749. Language: English. Summary Language: English.

L7   ANSWER 3 OF 6   MEDLINE

2001060249   Document Number: 20528604.   PubMed ID: 11074254.

Identification, cloning, and characterization of a major cat flea salivary allergen (Cte f 1). McDermott M J; Weber E; Hunter S; Stedman K E; Best E; Frank G R; Wang R; Escudero J; Kuner J; McCall C. (Heska Corporation, 1613 Prospect Parkway, Fort Collins, CO 80525, USA.. mcdermm@heska.com) . MOLECULAR IMMUNOLOGY, (2000 May) 37 (7) 361-75. Journal code: 7905289.

ISSN: 0161-5890. Pub. country: ENGLAND: United Kingdom. Language: English.

AB An 18 kDa protein isolated from saliva of the cat flea, *Ctenocephalides felis*, elicits a positive intradermal skin test (IDST) in 100 and 80% of experimental and clinical flea allergic dogs, respectively. Using solid-phase enzyme-linked immuno assay (ELISA), this protein detected **IgE** in 100 and 80% of experimental and clinical flea allergic dogs, respectively. A cDNA (pFS1) encoding a full-length Cte f 1 protein was isolated from a *C. felis* salivary gland cDNA library, using a combination of PCR and hybridization screening. This cDNA is 658 bp in length, and contains an open reading frame of 528 bp. The open reading frame encodes a protein of 176 amino acids, consisting of an 18 amino acid signal sequence and a 158 amino acid mature protein. The calculated molecular weight and pI of the mature protein are 18106 Da and 9.3, respectively. The protein, named Cte f 1, is the first novel major allergen described for **canine** flea allergy. Recombinant Cte f 1 (rCte f 1) was expressed in *Escherichia coli*, *Pichia pastoris* and baculovirus infected *Trichoplusia ni* cells. Approximately, 90% of the rCte f 1 expressed in *E. coli* accumulated in insoluble inclusion bodies, which could be refolded to a soluble mixture of disulfide isomers with partial **IgE** binding activity. Small quantities of an apparently correctly refolded form of rCte f 1, which had **IgE** binding activity equal to the native antigen, was isolated from the soluble fraction of *E. coli* cells. However, *P. pastoris* and baculovirus infected insect cells expressed and secreted a fully processed, correctly refolded and fully active form of rCte f 1. Mass spectrometry analysis of the active forms of rCte f 1 confirmed that eight intact disulfide bonds were present, matching the number observed in the native allergen. The relative ability of rCte f 1 to bind **IgE** in the serum of flea allergic animals, produced in these three expression systems, matched that of the native allergen. Competition ELISA demonstrated that approximately 90% of the specific **IgE** binding to native Cte f 1 could be blocked by the different forms of rCte f 1.

L7 ANSWER 4 OF 6 MEDLINE DUPLICATE 3  
 2000407793 Document Number: 20349799. PubMed ID: 10889305. In vitro **IgE** but not **IgG** production of **canine** peripheral blood B cells is inhibited by CD40 ligation. Goedert S; Schiessl B; Zunic M; Schiebl C; Mayer P; de Weck A L; Liehl E; Mudde G C. (Allergy Section, Department of Immuno-Dermatology, Novartis Research Institute, Brunnerstr. 59, A-1235, Vienna, Austria.. goedert@mpib-berlin.mpg.de) . VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, (2000 Jun 30) 75 (1-2) 135-49. JOURNAL code: 8002006. ISSN: 0165-2427. Pub. country: Netherlands. Language: English.

AB The aim of this study was to investigate in vitro **IgE** induction in peripheral **canine** B cells. CD21(+) B cells were purified from the peripheral blood of beagle dogs by positive selection via magnetic separation to a purity of >=95%. Subsequently, proliferation, and **IgG** and **IgE** production of **canine** B cells were investigated after stimulation with human recombinant Interleukin-4 (hrIL-4) and human recombinant Interleukin-2 (hrIL-2) in the presence or absence of CD40L-CD8 fusion protein (CD40L) of mouse origin. We could demonstrate that **canine** B cells react on hrIL-2 alone by proliferation and **IgG** production but not by **IgE** secretion, whereas activation with hrIL-4 induced proliferation and mainly **IgE** production. Together, both cytokines synergistically increased B cell proliferation as well as **IgG** and **IgE** production. We could also show that mouse CD40L induces proliferation of dog B cells, which is further enhanced by addition of hrIL-4. Unexpectedly, CD40L led to a dramatic decrease in the IL-4 mediated **IgE** secretion (82% inhibition on an average). In contrast, **IgG** production was not affected significantly by CD40L. The same effects of CD40L were observed when B cells were stimulated by a combination of IL-2 and IL-4 and this inhibition could not be abrogated by increasing the amounts of IL-4. In summary, activation of **canine**

B cells from peripheral blood by hrIL-4 in the presence or absence of hrIL-2 led to marked **IgE** production that is strongly and in a dose-dependent manner inhibited by CD40L. Stimulation of IgG production is not influenced by CD40L.

L7 ANSWER 5 OF 6 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
2000:140257 Document No.: PREV200000140257. Detection of allergen-specific **IgE** using a FcepsilonRIalpha/luciferase **fusion** protein.  
Weber, E. R. (1); McDermott, M. J. (1); Morales, T. H. (1); Snyder, S. E. (1); Miller, J. L. (1); Jensen, W. A. (1). (1) Heska Corporation, Fort Collins, CO USA. Journal of Allergy and Clinical Immunology., (Jan., 2000) Vol. 105, No. 1 part 2, pp. S114-S115. Meeting Info.: 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology. San Diego, California, USA March 03-08, 2000 American Academy of Allergy, Asthma and Immunology. ISSN: 0091-6749. Language: English. Summary Language: English.

L7 ANSWER 6 OF 6 MEDLINE DUPLICATE 4  
96005834 Document Number: 96005834. PubMed ID: 7558131. **Canine**  
**IgE** monoclonal antibody specific for a filarial antigen:  
production by a **canine** x murine heterohybridoma using B cells  
from a clinically affected lymph node. Gebhard D; Orton S; Edmiston D;  
Nakagaki K; DeBoer D; Hammerberg B. (College of Veterinary Medicine, North Carolina State University, Raleigh, USA. ) IMMUNOLOGY, (1995 Jul) 85 (3)  
429-34. Journal code: 0374672. ISSN: 0019-2805. Pub. country: ENGLAND:  
United Kingdom. Language: English.  
AB **Canine** popliteal lymph node cells taken at the onset of clinical  
disease from a rear limb infected with the filarial nematode *Brugia*  
*pahangi* were fused with mouse myeloma cell line P3X63.Ag8.653 cells. Of  
the several **canine** immunoglobulin-producing clones from this  
**fusion**, one was found to produce **canine IgE**  
specific for a filarial nematode antigen. The cell line has undergone  
limiting dilution cloning six times over the past 3 years and continues to  
produce monoclonal antibody of the **IgE** subclass at a rate of  
greater than 3 mg/l. Sodium dodecyl sulphate-polyacrylamide gel  
electrophoresis (SDS-PAGE) of the cell culture supernatant protein that  
bound to protein A beads, showed bands at molecular weights (MW) of  
approximately 75,000 and 25,000 that were characteristic of epsilon and  
kappa or lambda chains, respectively. A mouse monoclonal antibody specific  
for **canine IgE** bound the 75,000 MW band, as  
demonstrated by Western blot. Western blots of aqueous extracts of adult  
filarial nematodes demonstrated binding of the **canine**  
**IgE** monoclonal antibody to a single 35,000 MW peptide from *B.*  
*pahangi* but not *Dirofilaria immitis*; immunochemistry using frozen sections  
of adult worms, microfilariae and fourth stage larvae revealed focal  
binding of the monoclonal **IgE** to worm tissue adjacent to dorsal  
and ventral cords of only *Brugia* adults.

=> s (morsey m?/au or sheppard m?/au or wheeler d?/au)  
L8 5767 (MORSEY M?/AU OR SHEPPARD M?/AU OR WHEELER D?/AU)

=> s 18 and IgE  
L9 23 L8 AND IGE

=> dup remove 19  
PROCESSING COMPLETED FOR L9  
L10 7 DUP REMOVE L9 (16 DUPLICATES REMOVED)

=> d 110 1-7 cbib abs

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS  
2002:272796 Document No. 136:293510 Anti-allergic vaccines comprising  
peptides of Fc portion of **IgE** .epsilon. heavy chain and carrier

protein. **Morsey, Mohamad Ali; Sheppard, Michael George**  
**Wheeler, David Walter** (Pfizer Products Inc., USA). Eur. Pat.  
 Appl. EP 1195161 A2 20020410, 38 pp. DESIGNATED STATES: SI: AT, BE, CH,  
 DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI,  
 RO. (English). CODEN: EFXWDW. APPLICATION: EP 2001-307247 20010824.  
 PRIORITY: US 2000-PV228998 20000830.

**AB** The present invention provides comps. and methods for the use of  
 antigenic peptides derived from the Fc portion of the epsilon heavy chain  
 of an **IgE** mol. as vaccines for the treatment and prevention of  
**IgE**-mediated allergic disorders. In particular, the invention  
 provides comps., methods for the treatment and prevention of **IgE**  
 -mediated allergic disorders comprising an immunogenic amt. of one or more  
 antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4  
 domain of an **IgE** mol. and methods for the evaluation of  
**IgE** mediated allergies in dogs. The allergic disorder is asthma,  
 allergic rhinitis, gastrointestinal allergy, food allergy, eosinophilia,  
 conjunctivitis, or glomerular nephritis. The vaccine comps. may also  
 comprises carrier protein such as KLH, PhOE, rmlT, TraT and gD from BhV-1  
 virus; and adjuvant such as aluminum hydroxide, monophosphoryl lipid A,  
 Thr-MDP, immunostimulatory oligonucleotide, cytokine, interleukin 12,  
 interleukin 2, interleukin 1, saponin, cholera toxin, heat labile toxin,  
 etc.

**L10 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.**  
**2001:83036** Document No.: PREV200100083036. Effect of cytokines on **IgE**  
 switching by human B cells. Bitsaktsis, Con. (1); **Wheeler, D. (1)**  
 ; Kemeny, D. M. (1). (1) Dept. Immunology, Rayne Institute, 123  
 Coldharbour Lane, London, SE5-9NU UK. Immunology, (December, 2000) Vol.  
 101, No. Supplement 1, pp. 79. print. Meeting Info.: Annual Congress of  
 the British Society for Immunology Harrogate, UK December 05-08, 2000  
 British Society for Immunology. ISSN: 0019-2805. Language: English.  
 Summary Language: English.

**L10 ANSWER 3 OF 7 SCISEARCH COPYRIGHT 2002 ISI (R)**  
**1999:617501** The Genuine Article (R) Number: 223EE. Heligmosomoides polygyrus  
 immunomodulatory factor (IMF), targets T-lymphocytes. Telford G  
 (Reprint); **Wheeler D J**; Appleby P; Bowen J G; Pritchard D I.  
 KNOLL PHARMACEUT, RES DEPT R3, PENNYFOOT ST, NOTTINGHAM NG1 1GF, ENGLAND  
 (Reprint); RHONE-POULENC RORER, DAGENHAM RM10 7XS, ESSEX, ENGLAND; UNIV  
 NOTTINGHAM, DEPT LIFE SCI, NOTTINGHAM NG7 2RD, ENGLAND. PARASITE  
 IMMUNOLOGY (DEC 1998) Vol. 20, No. 12, pp. 601-611. Publisher: BLACKWELL  
 SCIENCE LTD. P O BOX 88, OSNEY MEAD, OXFORD OX2 ONE, OXON, ENGLAND. ISSN:  
 0141-9838. Pub. country: ENGLAND. Language: English.  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

**AB** Experiments were performed to investigate the immunological site of  
 action of an immunomodulatory factor (IMF), isolated from the  
 gastrointestinal nematode Heligmosomoides polygyrus. IMF inhibited  
 antibody production in murine and human 'T-helper (Th-2) driven'  
 immunoassays. The effects were mediated via T lymphocytes as T  
 cell-depleted cultures failed to respond to IMF, a result confirmed by  
 prepulsing discrete cell subsets with the immunomodulant. Although the  
 molecular nature and mode of action of IMF has yet to be determined it  
 would appear to be a relatively small nonproteinaceous molecule. From this  
 data, we suggest that H. polygyrus secretes a systemically-active IMF from  
 the intestinal lumen, to down-regulate Th-2 cell development in order to  
 promote its survival in a potentially immunologically hostile environment.

**L10 ANSWER 4 OF 7 MEDLINE** **DUPLICATE 1**  
**1999069260** Document Number: 99069260. PubMed ID: 9767464. Inhibition of  
 sCD23 and immunoglobulin E release from human B cells by a  
 metalloproteinase inhibitor, GI 129471. **Wheeler D J**; Parveen S;  
 Pollock K; Williams R. (Department of Cell Biology, Rhone-Poulenc-Rorer  
 Ltd, Dagenham Research Centre, Dagenham, Essex, UK. ) IMMUNOLOGY, (1998

Sep) 95 (1) 105-10. Journal code: 0374672. ISSN: 0019-2805. Pub. country: ENGLAND: United Kingdom. Language: English.

- AB Soluble CD23 (sCD23) has been proposed to play an important role in the up-regulation of immunoglobulin E (IgE) synthesis. Production of sCD23 is dependent on the proteolytic cleavage of membrane CD23, but the protease(s) involved in this process remain unknown. Preliminary data, obtained by testing a panel of protease inhibitors, suggested that this enzyme may be a zinc-dependent metalloproteinase. Therefore, we investigated the effect of a standard hydroxamate-type Zn<sup>2+</sup> metalloproteinase inhibitor (GI 129471) on both sCD23 and IgE release from human tonsillar B cells, stimulated with interleukin-4 (IL-4) and anti-CD40. Incubation of cells for 3 days with GI 129471 inhibited the production of sCD23 with an IC50 of 602 nm<sup>+</sup>/-3 nm (n=3), but by 14 days the activity of the compound against sCD23 had decreased by greater than threefold (IC50 2+/-0.26 microM; n=3). On the other hand, GI 129471 caused a potent inhibition of IgE production, with no apparent loss of activity over the culture period (14 days: IC50 250 nm<sup>+</sup>/-72 nm; n=3). Time-course studies showed that, despite loss of activity against sCD23, inhibition of sCD23 production early in the culture was able to cause a potent and long-lasting inhibitory effect on IgE. Furthermore, we also showed that the activity of GI 129471 is selective for IgE, as no effect was seen on immunoglobulin G1 (IgG1) or IgG4 production at test concentrations as high as 10 microM. These results support the hypothesis that metalloproteinases may be involved in the proteolytic cleavage of CD23 and subsequent regulation of IgE synthesis. Inhibition of the protease(s) responsible for such cleavage may be of value in the treatment of allergic disease.

L10 ANSWER 5 OF 7 MEDLINE DUPLICATE 2  
1998084452 Document Number: 98084452. PubMed ID: 9423836. The *Pseudomonas aeruginosa* quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Telford G; Wheeler D; Williams P; Tomkins P T; Appleby P; Sewell H; Stewart G S; Bycroft B W; Pritchard D I. (Department of Life Science, University of Nottingham, University Park, United Kingdom. ) INFECTION AND IMMUNITY, (1998 Jan) 66 (1) 36-42. Journal code: 0246127. ISSN: 0019-9567. Pub. country: United States. Language: English.

- AB Diverse gram-negative bacterial cells communicate with each other by using diffusible N-acyl homoserine lactone (AHL) signal molecules to coordinate gene expression with cell population density. Accumulation of AHLs above a threshold concentration renders the population "quorate," and the appropriate target gene is activated. In pathogenic bacteria, such as *Pseudomonas aeruginosa*, AHL-mediated quorum sensing is involved in the regulation of multiple virulence determinants. We therefore sought to determine whether the immune system is capable of responding to these bacterial signal molecules. Consequently the immunomodulatory properties of the AHLs N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) and N-(3-oxohexanoyl)-L-homoserine lactone (OHHL) were evaluated in murine and human leukocyte immunoassays in vitro. OdDHL, but not OHHL, inhibited lymphocyte proliferation and tumor necrosis factor alpha production by lipopolysaccharide-stimulated macrophages. Furthermore, OdDHL simultaneously and potentially down-regulated the production of IL-12, a Th-1-supportive cytokine. At high concentrations (>7 x 10<sup>-5</sup> M) OdDHL inhibited antibody production by keyhole limpet hemocyanin-stimulated spleen cells, but at lower concentrations (<7 x 10<sup>-5</sup> M), antibody production was stimulated, apparently by increasing the proportion of the immunoglobulin G1 (IgG1) isotype. OdDHL also promoted IgE production by interleukin-4-stimulated human peripheral blood mononuclear cells. These data indicate that OdDHL may influence the Th-1-Th-2 balance in the infected host and suggest that, in addition to regulating the expression of virulence determinants, OdDHL may contribute to the pathogenesis of *P. aeruginosa* infections by functioning as a virulence determinant per se.

- L10 ANSWER 6 OF 7 MEDLINE DUPLICATE 3  
 96381527 Document Number: 96381527. PubMed ID: 8789540. Peripheral blood based T cell-containing and T cell-depleted culture systems for human **IgE** synthesis: the role of T cells. **Wheeler D J**; Robins R A; Pritchard D I; Bundick R V; Shakib F. (Department of Immunology, University of Nottingham, UK. ) CLINICAL AND EXPERIMENTAL ALLERGY, (1996 Jan) 26 (1) 28-35. Journal code: 8906443. ISSN: 0954-7894. Pub. country: ENGLAND: United Kingdom. Language: English.
- AB BACKGROUND: Comparable T cell-containing and T cell-depleted culture systems for human **IgE** synthesis are currently not available. OBJECTIVE: This has prompted us to develop peripheral blood mononuclear cell (PBMC) based culture systems for human **IgE** synthesis in the presence and absence of T cells. METHODS: In this paper we describe simplified conditions for in vitro synthesis of high levels of **IgE** by human peripheral blood B cells, both in T cell-containing cultures and in anti-CD40 stimulated T cell-depleted cultures. RESULTS: T cell-depleted cultures released approximately 20 times more **IgE** [range 410-2220 ng/mliter (mean 1270 ng/mliter); based on six experiments using cells from three donors] than did T cell-containing cultures [range 23-105 ng/mliter (mean 58 ng/mliter); based on 15 experiments using cells from three donors]. Reconstitution experiments were performed to investigate the role of T cells on **IgE** synthesis. Adding T cells back to the anti-CD40 stimulated T cell-depleted cultures resulted in a dose-dependent inhibition of **IgE** production. In the absence of anti-CD40 low numbers of T cells stimulated, while high numbers suppressed, **IgE** production: the optimal ratio of T cells to non-T cells for maximal **IgE** production was found to be 1:1. At this ratio, irradiated (non-replicating) T cells supported a much greater **IgE** synthesis than did non-irradiated T cells. CONCLUSION: The development of these systems provides directly comparable T cell-containing and T cell-depleted cultures for human **IgE** synthesis from peripheral blood, allowing further study of the role of T cells in **IgE** regulation. These systems will also be of use for determining whether potential modulators of **IgE** synthesis act on the T cells or on other cell types.

- L10 ANSWER 7 OF 7 MEDLINE DUPLICATE 4  
 96003955 Document Number: 96003955. PubMed ID: 7554405. Potentiation of in vitro synthesis of human **IgE** by cyclosporin A (CsA). **Wheeler D J**; Robins A; Pritchard D I; Bundick R V; Shakib F. (Division of Molecular and Clinical Immunology, University of Nottingham, Medical School, UK. ) CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (1995 Oct) 102 (1) 85-90. Journal code: 0057202. ISSN: 0009-9104. Pub. country: ENGLAND: United Kingdom. Language: English.
- AB In this study, we investigated the modulatory effects of CsA on in vitro synthesis of **IgE**, IgG1 and IgG4 by human peripheral blood mononuclear cells (PBMC). In contrast to its known immunosuppressive effect, we have demonstrated that a low dose of CsA (10(-7) M, 120 ng/ml) potentiated **IgE** production by up to 40-fold (i.e. from 33 +/- 4.5 to 1346 +/- 290 ng/ml). This potentiation was specific for **IgE** since no such effect was demonstrable with IgG1 and IgG4. Potentiation of **IgE** synthesis by CsA in the PBMC cultures was partly due to CsA acting on T cells, as demonstrated by the addition of CsA-treated T cells to T cell-depleted cultures. However, potentiation was also demonstrable in a T cell-depleted, anti-CD40-stimulated culture (four-fold increase from 400 +/- 48 to 1606 +/- 127 ng/ml). Our data therefore suggest that there are at least two mechanisms for CsA-induced potentiation of **IgE** synthesis, one T cell-dependent and the other T cell-independent. The clinical implications of these findings are discussed with regard to the use of CsA in the treatment of Th2-mediated diseases.



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

38.08

38.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.62

-0.62

STN INTERNATIONAL LOGOFF AT 15:55:27 ON 17 JUL 2002